Miracle treatment for melanoma?
Added: Tuesday 3 June 2014
Two experimental drugs have raised hopes of drastically improving outcomes for people with advanced melanoma. Pembrolizumab and nivolumab both work by allowing the body's immune system to recognise and attack the cancer. They do this by blocking the biological pathways that cancers use to disguise themselves from the immune system. The results of the recent trials are considered remarkable because one-year survival rates for advanced Stage Four melanoma are low: 10 percent for men and 35 percent for women. The pembrolizumab trial resulted in a 70 percent one-year survival rate.
In order to be able to see the content from the www.medscape.com pages, please create first a free account at following link: